top of page
Blackstone Life Sciences' $3.1BN sale of Anthos Therapeutics to Novartis
Novartis reacquires Anthos from Blackstone after cardiovascular drug abelacimab shows promise. A successful PE/Biopharma model emerges.
bottom of page
top of page
bottom of page